DNA Script is a leading company in manufacturing de novo synthetic nucleic acids using a proprietary enzymatic technology. DNA Script's approach leverages nature's billions of years of evolution in synthesizing DNA to set a new standard for how nucleic acids are made and accelerate the adoption of synthetic biology across diverse disciplines such as biopharma, sustainable chemistry and data storage. DNA Script’s first product is the SYNTAX system, the first world's first benchtop DNA printer using enzymatic synthesis.
To date, DNA Script has raised over $100M of financing, mostly through leading investors such as Casdin, Agilent, Danaher, LSP, Bpifrance, Illumina Ventures, Merck Ventures, Sofinnova Partners, Kurma Partners, Idinvest.
DNA Script has its research facility headquartered in Paris, France, and has its commercial and development teams in South San Francisco.